TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CytoDyn ( (CYDY) ) has shared an update.
CytoDyn announced the appointment of Robert E. Hoffman as Chief Financial Officer, effective May 15, 2025, succeeding Mitch Cohen, who served as interim CFO. Hoffman’s extensive experience in the biotech sector is expected to bolster CytoDyn’s financial strategy and support its clinical development pipeline, particularly in oncology.
More about CytoDyn
CytoDyn is a clinical-stage biotechnology company focused on developing and commercializing leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor, which is implicated in various disease processes. The company is exploring leronlimab’s potential in treating infectious diseases, oncology, and autoimmune conditions.
Average Trading Volume: 2,960,191
Technical Sentiment Signal: Buy
Current Market Cap: $400.4M
For a thorough assessment of CYDY stock, go to TipRanks’ Stock Analysis page.